Clinical Trial Update: A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial evaluating efficacy, safety, tolerability, and exposure of repeat-dose Sepofarsen (QR-110) in Leber Congenital Amaurosis 10 (LCA10) is ongoing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eye Diseases
• Leber Congenital Amaurosis 10
• Retinal Disease
• Vision Disorders

Drugs mentioned

• Sepofarsen (sepofarsen)

Snippet

Sponsor: ProQR Therapeutics | Conditions: Leber Congenital Amaurosis 10, Blindness | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING